Wpływ krótkotrwałego leczenia skojarzonego simwastatyną i ezetimibem na stężenie adipokin w osoczu pacjentów na izolowaną hipercholesterolemię

Abstract

Introduction: Although several studies have assessed plasma adipokines in patients treated with hypolipidemic agents, these studies have provided contrasting results. Material and methods:This study included 19 high-risk patients with elevated total and LDL cholesterol levels treated with simvastatin (40 mg daily) and ezetimibe (10 mg daily). Plasma levels of leptin, adiponectin, visfatin, tumour necrosis factor-α, free fatty acids as well as C-reactive protein were measured before and after 30 days of treatment. High-risk hypercholesterolemic patients were compared with 17 age-, sex-and weight-matched healthy subjects who did not receive any treatment. Results: Compared to the healthy subjects, hypercholesterolemic patients exhibited lower plasma levels of adiponectin, as well as higher plasma levels of the remaining adipokines. Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-α, as well as increased plasma levels of adiponectin. The treatment also reduced free fatty acids and C-reactive protein.Conclusions: High-risk hypercholesterolemic patients with elevated cholesterol levels are characterised by abnormal production of adipose tissue hormones. Short-term treatment with simvastatin and ezetimibe partially restores adipokine production and inhibits low-grade inflammation. (Endokrynol Pol 2014; 65 (4): 275-280)

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue

“…Ezetimibe was shown to reduce visfatin, while increasing adiponectin plasma levels [ 155 , 156 ]. The combination of ezetimibe-simvastatin treatment for 30 days was able to partially revert AT dysfunction and decrease systemic inflammation, independently of the lipid-lowering effect [ 157 ]. The same combination also seems to decrease leptin, visfatin, and TNF α and increase adiponectin levels [ 157 ].…”